In a phase Ib clinical trial assessing the safety and the antitumor activity of the anti-PD-1 antibody pembrolizumab, 22 patients with locally advanced or metastatic differentiated thyroid cancer, positive for PD-L1 expression, who have never received anti-cancer monoclonal antibody therapy in the last 4 weeks before treatment, or targeted therapy in the last 2 weeks prior the treatment. This evidence concerns the gene CD274 and cancer.